BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 29761574)

  • 1. Association between hyperinsulinaemia and laminitis severity at the time of pituitary pars intermedia dysfunction diagnosis.
    Tadros EM; Fowlie JG; Refsal KR; Marteniuk J; Schott HC
    Equine Vet J; 2019 Jan; 51(1):52-56. PubMed ID: 29761574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lamellar pathology in horses with pituitary pars intermedia dysfunction.
    Karikoski NP; Patterson-Kane JC; Singer ER; McFarlane D; McGowan CM
    Equine Vet J; 2016 Jul; 48(4):472-8. PubMed ID: 25869529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with survival, laminitis and insulin dysregulation in horses diagnosed with equine pituitary pars intermedia dysfunction.
    Horn R; Bamford NJ; Afonso T; Sutherland M; Buckerfield J; Tan RHH; Secombe CJ; Stewart AJ; Bertin FR
    Equine Vet J; 2019 Jul; 51(4):440-445. PubMed ID: 30417404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BEVA primary care clinical guidelines: Diagnosis and management of equine pituitary pars intermedia dysfunction.
    Menzies-Gow NJ; Banse HE; Duff A; Hart N; Ireland JL; Knowles EJ; McFarlane D; Rendle D
    Equine Vet J; 2024 Mar; 56(2):220-242. PubMed ID: 37795557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma fructosamine concentrations in horses with pituitary pars intermedia dysfunction with and without laminitis.
    Knowles EJ; Menzies-Gow NJ; Mair TS
    Equine Vet J; 2014 Mar; 46(2):249-51. PubMed ID: 23663105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of suspected pituitary pars intermedia dysfunction in horses with laminitis.
    Donaldson MT; Jorgensen AJ; Beech J
    J Am Vet Med Assoc; 2004 Apr; 224(7):1123-7. PubMed ID: 15074858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The oral glucose test predicts laminitis risk in ponies fed a diet high in nonstructural carbohydrates.
    Meier AD; de Laat MA; Reiche DB; Pollitt CC; Walsh DM; McGree JM; Sillence MN
    Domest Anim Endocrinol; 2018 Apr; 63():1-9. PubMed ID: 29172109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prevalence of endocrinopathic laminitis among horses presented for laminitis at a first-opinion/referral equine hospital.
    Karikoski NP; Horn I; McGowan TW; McGowan CM
    Domest Anim Endocrinol; 2011 Oct; 41(3):111-7. PubMed ID: 21696910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotypic, hormonal, and clinical characteristics of equine endocrinopathic laminitis.
    de Laat MA; Sillence MN; Reiche DB
    J Vet Intern Med; 2019 May; 33(3):1456-1463. PubMed ID: 30697823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of horse owners' ability to recognise equine laminitis: A cross-sectional study of 93 veterinary diagnosed cases in Great Britain.
    Pollard D; Wylie CE; Verheyen KLP; Newton JR
    Equine Vet J; 2017 Nov; 49(6):759-766. PubMed ID: 28543943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiological investigation of insulin dysregulation in Shetland and Welsh ponies in Australia.
    Clark BL; Norton EM; Bamford NJ; Randhawa IAS; Kemp KL; McCue ME; Bertin FR; Stewart AJ
    Equine Vet J; 2024 Mar; 56(2):281-290. PubMed ID: 38173146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic frequency, response to therapy, and long-term prognosis among horses and ponies with pituitary par intermedia dysfunction, 1993-2004.
    Rohrbach BW; Stafford JR; Clermont RS; Reed SM; Schott HC; Andrews FM
    J Vet Intern Med; 2012; 26(4):1027-34. PubMed ID: 22524260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathology of Natural Cases of Equine Endocrinopathic Laminitis Associated With Hyperinsulinemia.
    Karikoski NP; McGowan CM; Singer ER; Asplin KE; Tulamo RM; Patterson-Kane JC
    Vet Pathol; 2015 Sep; 52(5):945-56. PubMed ID: 25232034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Equine laminitis: comparative histopathology 48 hours after experimental induction with insulin or alimentary oligofructose in standardbred horses.
    de Laat MA; van Eps AW; McGowan CM; Sillence MN; Pollitt CC
    J Comp Pathol; 2011 Nov; 145(4):399-409. PubMed ID: 21429503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Equine laminitis: induced by 48 h hyperinsulinaemia in Standardbred horses.
    de Laat MA; McGowan CM; Sillence MN; Pollitt CC
    Equine Vet J; 2010 Mar; 42(2):129-35. PubMed ID: 20156248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age over 25 years, but not plasma adrenocorticotropic hormone con-cen-tration above the seasonally adjusted reference range is predictive for radio-graphically assessed changes of chronic laminitis in elderly horses.
    Christen G; Precht C; van der Kolk J; Fouché N; Gerber V
    Schweiz Arch Tierheilkd; 2020 Dec; 162(12):781-785. PubMed ID: 33263545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of laminitis by prolonged hyperinsulinaemia in clinically normal ponies.
    Asplin KE; Sillence MN; Pollitt CC; McGowan CM
    Vet J; 2007 Nov; 174(3):530-5. PubMed ID: 17719811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The application of a new laminitis scoring method to model the rate and pattern of improvement from equine endocrinopathic laminitis in a clinical setting.
    Meier A; McGree J; Klee R; Preuß J; Reiche D; de Laat M; Sillence M
    BMC Vet Res; 2021 Jan; 17(1):16. PubMed ID: 33413384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Equine laminitis: what is all the hype about hyperinsulinaemic laminitis?
    Wylie CE
    Vet J; 2013 May; 196(2):139-40. PubMed ID: 23168265
    [No Abstract]   [Full Text] [Related]  

  • 20. Adrenocorticotropin concentration following administration of thyrotropin-releasing hormone in healthy horses and those with pituitary pars intermedia dysfunction and pituitary gland hyperplasia.
    Beech J; Boston R; Lindborg S; Russell GE
    J Am Vet Med Assoc; 2007 Aug; 231(3):417-26. PubMed ID: 17669045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.